Breaks Categories: News

TuesdayNov 25, 2025 9:00 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Rising Biotech Valuations

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial highlighting how fair-value adjustments under U.S. GAAP are emerging as key indicators of scientific and commercial progress across the biotech sector. The article spotlights Oncotelic’s upcoming fair-value update on its 45% ownership in JV partner GMP Bio, following an independent assessment showing a significant increase in asset value, reinforcing the company’s position among leaders advancing oncology treatments. To view the full press release, visit https://ibn.fm/aAZ0k About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is…

Continue Reading

MondayNov 24, 2025 9:40 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Chairman Presentation at NobleCon21

Nutriband (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets’ annual emerging growth equity conference, on Dec. 3 at 9:30 a.m. Eastern at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida. Investors and guests may attend at a discounted rate using code NTRBNOBLECON, and a high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days. To view the full press release, visit https://ibn.fm/CqOt4 About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our…

Continue Reading

MondayNov 24, 2025 9:00 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Engages NE Holdings to Guide Nasdaq Listing Strategy

HealthLynked (OTCQB: HLYK) said it has entered a Capital Market Advisory Agreement with “NE Holdings LLC,” a Florida-based consulting firm focused on senior exchange readiness and capital markets strategy, to support the Company plan to uplist to Nasdaq in the first half of 2026. NE Holdings will lead corporate and financial readiness efforts, oversee audit and compliance planning, assist with capital structure optimization, coordinate introductions to investment banks and key market participants, and advise on governance as HealthLynked advances its Nasdaq listing roadmap and broader public-market expansion strategy. To view the full press release, visit https://ibn.fm/ZxSyM About HealthLynked Corp. HealthLynked…

Continue Reading

FridayNov 21, 2025 9:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends

Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how fair-value remeasurements under GAAP are becoming key indicators of real scientific and commercial progress in late-stage biotech pipelines. The piece notes that Oncotelic is preparing for a significant fair-value remeasurement of its 45% stake in JV entity GMP Bio following a new independent valuation suggesting a potential step-up in asset value, reinforcing the company’s position as it advances its oncology efforts. To view the full press release, visit https://ibn.fm/YS5OI About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading

ThursdayNov 20, 2025 11:28 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Preliminary $1.7B Pipeline Valuation From Joint Venture Partner 

Oncotelic Therapeutics (OTCQB: OTLC) today announced that joint venture partner GMP Bio has received an independent Frost & Sullivan (Hong Kong) valuation estimating the potential value of its therapeutic pipeline at approximately $1.7 billion, implying about $765 million for Oncotelic’s 45% stake. The non-binding, forward-looking analysis does not represent fair value under U.S. GAAP, and Oncotelic has initiated a separate ASC-compliant valuation that will support future financial reporting. Depending on the results, the Company may record a higher carrying value for its minority interest in upcoming periods, consistent with applicable fair-value measurement standards. CEO Dr. Vuong Trieu said the valuation…

Continue Reading

WednesdayNov 19, 2025 9:42 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases with unmet medical need, completed enrollment of the 50 patients required for the interim analysis in its 80-patient confirmatory Phase 3 FLASH2 study evaluating HyBryte (TM) in cutaneous T-cell lymphoma. The interim analysis is slated for the second quarter of 2026, with topline data expected in the second half of the year. The Company noted an overall blinded response rate of 48 percent among patients who have completed treatment to date, exceeding the anticipated 25 percent rate used in the study’s powering assumptions. Investigators report safety findings consistent…

Continue Reading

MondayNov 17, 2025 11:05 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study 

CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in development for glioblastoma and other CNS tumors. The Company noted Phase 1 data showing potential BBB penetration and tumor responses, including 3 complete and 9 partial responses among 23 evaluable patients treated with TPI 287 plus bevacizumab, and plans to engage the FDA early next year on a registration-focused Phase 2 trial design in recurrent GBM. For the quarter, CNS reported a net loss of $3.3 million, R&D expenses of $2.2 million and G&A expenses of $1.1 million, ending the…

Continue Reading

MondayNov 17, 2025 10:47 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs

NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 results and outlined progress across its clinical programs, noting its first revenue-generating activities and key regulatory milestones for NRX-100 and NRX-101. The Company highlighted expanded Fast Track status and an active Expanded Access program for NRX-100 in suicidal depression, continued advancement of its NDA supported by large-scale real-world ketamine data, and an ANDA pathway for its preservative-free ketamine KETAFREE that remains on track for a Q2 2026 GDUFA date. NRx also noted FDA communication with no major deficiencies in its revised ANDA filing and ongoing efforts to remove benzethonium chloride from commercial ketamine…

Continue Reading

FridayNov 14, 2025 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates

HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510(k) review with anticipated clearance by year end. The company is advancing commercial readiness, including a new partnership with HeartNexus for 24/7 cardiologist review services, alongside new scientific data presented at AHA Scientific Sessions and HRX Live 2025 and an expanded global IP portfolio of 24 issued patents. For the quarter, R&D expenses were $3.3 million, G&A expenses were $2.0 million, net loss was $5.3 million and cash totaled $1.9 million. HeartBeam will discuss…

Continue Reading

ThursdayNov 13, 2025 1:08 pm

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) Reports Q3 2025 Results Highlighted by Cost Reductions and Improving Healthcare Trends

NextPlat (NASDAQ: NXPL, NXPLW) reported third-quarter 2025 results showing consolidated revenue of about $13.8 million compared with $15.4 million in the prior year, primarily reflecting lower 340B pharmacy contract revenue before late-quarter customer re-engagement efforts drove improving prescription volumes expected to continue into Q4. Gross margin declined to 19.9% from 23.2% on lower Healthcare and e-commerce margins tied to reduced 340B revenue, new airtime costs and temporary customer rate adjustments. Operating expenses fell to roughly $4.7 million from $7.8 million as stock-based compensation, executive compensation and headcount decreased under companywide efficiency measures, contributing to a reduced net loss of about…

Continue Reading